Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old

NCT06282692 is registered in ClinicalTrials.gov with Dr. Soetomo General Hospital as lead sponsor.

NCT NCT06282692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Lead sponsor
Dr. Soetomo General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 19, 2023
Completion date
July 19, 2024
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, covid-19 vaccines